Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Synbalance Srl operates within the Biotechnology & Pharmaceuticals technology area and currently faces 3 pending office actions. These actions are spread across 3 distinct examiners. This distribution between actions and examiners indicates a diversified prosecution environment where pending matters are reviewed by different people, potentially leading to varied outcomes across the portfolio.
The busiest examiner for this portfolio is CELSA, BENNETT M, who is responsible for 1 busiest examiner pending action. Given that there are multiple pending office actions in total, the workload is evenly distributed among the assigned examiners. The portfolio also spans several distinct art units. This distribution suggests that the company's intellectual property covers a variety of specific sub-disciplines within the biotechnology field, requiring engagement with multiple specialized areas of the patent office simultaneously to secure its patent rights.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CELSA, BENNETT M | 1 | 33.3% | +0.0% |
| FAN, LYNN Y | 1 | 47.3% | +49.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18719160 | PROBIOTIC COMPOSITIONS AND THEIR USE IN MODULATING ALLERGY-TYPE INFLAMMATORY ACTIVITY | CELSA, BENNETT M | 20d |
| 18288361 | PROBIOTIC COMPOSITIONS USEFUL IN THE PREVENTION AND/OR TREATMENT OF METABOLIC SYNDROME AND RELATED DISORDERS | FAN, LYNN Y | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18288361 | PROBIOTIC COMPOSITIONS USEFUL IN THE PREVENTION AND/OR TREATMENT OF METABOLIC SYNDROME AND RELATED DISORDERS | FAN, LYNN Y | — |
| Art Unit | Apps |
|---|---|
| 1651 | 1 |
| 1759 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18719160 | PROBIOTIC COMPOSITIONS AND THEIR USE IN MODULATING ALLERGY-TYPE INFLAMMATORY ACTIVITY | CELSA, BENNETT M | 1651 | §103§112 | Final Rejection | 20d | Pending | Jun 12, 2024 |
| 18288361 | PROBIOTIC COMPOSITIONS USEFUL IN THE PREVENTION AND/OR TREATMENT OF METABOLIC SYNDROME AND RELATED DISORDERS | FAN, LYNN Y | 1759 | §103§112 | Non-Final OA | — | Pending | Oct 25, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial